Background
Demand for GLP-1 agonists such as dulaglutide, which are funded in New Zealand for the treatment of Diabetes, has grown globally and has resulted in a supply constraint. Eli Lilly has advised us that the supply constraint will continue until the end of 2024.
Eli Lilly’s statement about the shortage(external link)
You are viewing: Why Is Trulicity Unavailable
The suppliers of both dulaglutide (Eli Lilly) and liraglutide (Novo Nordisk) have advised Pharmac that they can only secure enough stock for people currently taking these medicines.
To ensure people currently taking dulaglutide and liraglutide can continue to access these medicines, Pharmac amended the Special Authority criteria for GLP-1 Agonists from 1 November 2023. New initiations are restricted to people with type 2 diabetes who are high-risk and have no other appropriate treatment options.
Affected products
- Chemical: dulaglutide
- Brand: Trulicity
- Supplier: Eli Lilly
- Measure: Inj 1.5mg per 0.5 ml, prefilled pen
- Pharmacode: 2617722
Pharmaceutical Schedule listing for dulaglutide(external link)
- Chemical: liraglutide
- Brand: Victoza
- Supplier: Novo Nordisk
- Measure: Inj 6 mg per ml, 3 ml prefilled pen
- Pharmacode: 2653990
Pharmaceutical Schedule listing for liraglutide(external link)
People who are taking dulaglutide or liraglutide
Read more : Why Does My Water Taste Weird
We understand it is frustrating when there are supply issues with medicines, and we are doing what we can to safeguard the supply for people currently taking dulaglutide and liraglutide.
The shortage will be variable from pharmacy to pharmacy due to differences in local and wholesaler supply. If you are struggling to source these treatments from a pharmacy, email [email protected]
We are working with our clinical advice network to identify what additional steps we can take to ensure you can continue to access your medicine during this global supply issue.
Learn more about these treatments:
- Dulaglutide (branded as Trulicity) (external link)
- Liraglutide (branded as Victoza)(external link)
Information for pharmacists
We appreciate all you are doing to support people through this supply issue. Thank you for reaching out to let us know about the problems you’re facing.
Both suppliers are, or will be, manually allocating stock to wholesalers to avoid regional out-of-stock events. If you have any questions about the supply of these agents, please talk to your wholesaler in the first instance.
Read more : Why Is Shooting So Hard In 2k23
Pharmac will continue to work closely with Eli Lilly and Novo Nordisk to monitor stock levels, and take any additional measures as required to ensure patients continue to receive their medication.
Information for healthcare professionals
There are global constraints on the supply of GLP-1 agonists, which are funded in New Zealand for the treatment of Diabetes. Our suppliers of both dulaglutide (Eli Lilly) and liraglutide (Novo Nordisk) do not have enough stock to cater to the rapid increase in demand. For this reason, we are trying our best to preserve dulaglutide and liraglutide for people already taking it for type 2 diabetes, on advice from our Diabetes Advisory Committee.
We want to reduce the risk of people being unable to fill their prescriptions. To ensure people currently taking dulaglutide and liraglutide can continue to access these medicines, Pharmac amended the Special Authority criteria for GLP-1 Agonists from 1 November 2023. New initiations are restricted to people with type 2 diabetes who are high-risk and have no other appropriate treatment options.
We understand it is frustrating when there are supply issues with medicines. We all have a role in ensuring that stock is available to those currently accessing the treatment.
We are working with our clinical advice network to identify what additional steps we can take to ensure people can continue to access their medicine during this global supply issue.
Who to contact
If you have questions, email [email protected]
If you have questions about how to treat type 2 diabetes, please talk to your health professional.
Source: https://t-tees.com
Category: WHY
